Short Interest in Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Expands By 49.4%

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 103,800 shares, a growth of 49.4% from the January 15th total of 69,500 shares. Approximately 15.2% of the shares of the company are sold short. Based on an average trading volume of 69,600 shares, the days-to-cover ratio is currently 1.5 days.

Qualigen Therapeutics Trading Up 9.7 %

Shares of QLGN stock opened at $3.71 on Friday. The stock has a 50 day moving average of $3.93 and a two-hundred day moving average of $6.29. Qualigen Therapeutics has a 12 month low of $2.96 and a 12 month high of $29.43.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.